Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Mark J. Biagi

Mark J. Biagi


Clinical Assistant Professor, College of Pharmacy - Pharmacy Practice
Clinical Instructor, College of Pharmacy - Pharmacy Practice

Related Sites:

Teaching and Supervision Heading link

Undergrad Resrch Pharm Pract (PMPR 380), 1/11/2021 – 4/30/2021
PHAR 520: Clinical Pharmaceutics, Pharmacokinetics, and Pharmacogenomics (PHAR 520), 8/17/2020 – Present
PHAR 435: Pharmacokinetics (PHAR 435), 8/26/2019 – 12/6/2019
Spec Project in Pharm Pract (PMPR 390), 8/26/2019 – 12/6/2019
Spec Project in Pharm Pract (PMPR 390), 8/26/2019 – 12/6/2019
Antimicrobial Use in Pregnancy, 2018 – Present
Antimicrobial Dosing in Obesity, 2017 – 2018
Management of Antiretroviral Resistance, 2016 – 2016
Review of Psychotropic Medications, 2016 – 2016

Selected Grants

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients, Merck Sharp & Dohme Corp., 1/6/2022 - 1/6/2025, No Obligated Amount Set; Anticipated Amount: $137232.72

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients, Merck Sharp & Dohme Corp., 1/6/2022 - 1/6/2025, No Obligated Amount Set; Anticipated Amount: $137232.72

ACTIV-4c: COVID-19 Post-Hospital Thrombosis Prevention Study, National Institutes of Health., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set

Real World Multicenter Observational Study of Imipenem-Cilastatin-Relebactam for Gram-Negative Infections, Merck & Co., Inc.., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set

Multicenter Observational Study of Dalbavancin for Invasive Bloodstream Infections, Allergan Inc.., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set

ACTIV-4 ACUTE: COVID-19 Acute Inpatient Antithrombotic Study, National Institutes of Health., 10/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set

Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to those on Vancomycin and Ceftolozane-Tazobactam, Merck & Co.., 8/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set

Real-world experience with eravacycline at academic hospital systems, Tetraphase Pharmaceuticals., 2/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set

Aztreonam + ceftazidime/avibactam against Stenotrophomonas maltophilia, Cystic Fibrosis Foundation., 6/1/2019 - 11/30/2020, Obligated Amount: $54000; Anticipated Amount: $54000

Selected Publications

Alosaimy, S, Morrisette, T, Lagnf, AM, Rojas, LM, King, MA, Pullinger, BM, Hobbs, ALV, Perkins, NB, Veve, MP, Bouchard, J, Gore, T, Jones, B, Truong, J, Andrade, J, Huang, G, Cosimi, R, Lena, SKB, Molina, KC, Biagi, M, Pierce, M, Scipione, MR, Zhao, JJ, Davis, SL, Rybak, MJ. (2022). Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiology Spectrum, 10, (5). doi:10.1128/spectrum.00479-22.

Pierce, M, Slipke, W, Biagi, M. (2022). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Bordetella bronchiseptica Co-Infection in a Stem Cell Transplant Patient. Antibiotics, 11, (9). doi:10.3390/antibiotics11091200.

Vialichka, A, Biagi, M, Meyer, K, Wu, T, Shajee, A, Tan, X, Wenzler, E. (2022). Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values. Microbiology Spectrum, 10, (4). doi:10.1128/spectrum.02705-21.

Abbey, T, Vialichka, A, Jurkovic, M, Biagi, M, Wenzler, E. (2022). Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility. Microbiology Spectrum, 10, (3). doi:10.1128/spectrum.00542-22.

Biagi, M, Lee, M, Wu, T, Shajee, A, Patel, S, Deshpande, LM, Mendes, RE, Wenzler, E. (2022). Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales. Diagnostic Microbiology and Infectious Disease, 103, (2). doi:10.1016/j.diagmicrobio.2022.115674.

Rebold, N, Morrisette, T, Lagnf, AM, Alosaimy, S, Holger, D, Barber, K, Justo, JA, Antosz, K, Carlson, TJ, Frens, JJ, Biagi, M, Kufel, WD, Moore, WJ, Mercuro, N, Raux, BR, Rybak, MJ. (2021). Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infectious Diseases, 8, (12). doi:10.1093/ofid/ofab554.

Biagi, Mark, Slipke, Wendy, Smalley, Alexa, Tsaras, Geoffrey. (2021). Successful treatment of trichomoniasis with tinidazole following desensitization in a patient allergic to metronidazole.. Int J STD AIDS, 32, (1), 89-91. doi:10.1177/0956462420963912.

Lee, Michelle, Abbey, Taylor, Biagi, Mark, Wenzler, Eric. (2021). Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.. Diagnostic Microbiology and Infectious Disease, 99, (1). doi:10.1016/j.diagmicrobio.2020.115227.

Alosaimy, Sara, Lagnf, Abdalhamid M, Molina, Kyle, King, Madeline, Pullinger, Benjamin, Tart, Serina, Jones, Bruce M, Claeys, Kimberly C, Truong, James, Andrade, Justin A, Biagi, Mark, Pierce, Michael, Cosimi, Reese, Hobbs, Athena LV, Perkins, Nicholson, Huang, Glen, Veve, Michael, Morrisette, Taylor, Davis, Susan L, Davis, Susan L, Rybak, Michael J. (2020). 1577. Real-World, Multicenter Experience with Eravacycline for Various Infections. Open Forum Infectious Diseases, 7, (Suppl 1), s787-s787. doi:10.1093/ofid/ofaa439.1757.

Professional Leadership

Clostridioides difficile committee, SwedishAmerican Hospital, 2/1/2020 - Present

Education

Degrees:
Doctor of Pharmacy, University of Illinois at Chicago, United States, 2016
Bachelor of Science, University of Illinois at Chicago, United States, 2012

Postgraduate Training:
PGY-1 Pharmacy Practice Resident, Franciscan Health, United States, 2017